ArticleBMC cancer2026
The role of PET/CT in preoperative decision-making for secondary cytoreduction in recurrent ovarian cancer.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSecondary cytoreductive surgery is a feasible treatment option in recurrent ovarian cancer. Patient selection for surgery remains challenging, as conventional imaging, such as CT and MRI, is unreliable for predicting complete gross resection. PET/CT is a modality that combines metabolic and anatomical imaging. Although there are studies supporting the use of PET/CT in ovarian cancer, there is very limited evidence specifically assessing PET/CT-guided selection for secondary cytoreductive surgery under the latest eligibility criteria. This study aims to evaluate the added value of PET/CT for predicting no residual tumor volume after secondary surgical cytoreduction.
methodsWe conducted a retrospective data collection on patients diagnosed with ovarian cancer who underwent a PET/CT examination between 2018 and 2023 in our center. Patients with suspected recurrence considered for secondary cytoreduction based on conventional imaging and clinical criteria, were included in our analysis. Besides descriptive statistics we performed decision curve analysis (DCA) to determine the added value of PET/CT in surgical decision-making.
results22 patients were potentially eligible for secondary debulking according to clinical criteria and conventional imaging findings. 13/22 patients were found to be operable based on preoperative PET/CT results, and 11/13 had a successful resection (no gross residual tumor) (PPV: 85%). 9/22 patients were found ineligible for secondary cytoreduction based on PET/CT results. 7/9 had inoperable lesions, and in two cases, no malignant lesions were detected. Decision curve analysis showed that PET/CT provided superior clinical utility compared to both conventional imaging and a “treat none” approach, yielding a higher net benefit across a broad range of surgical decision thresholds.
conclusionsOur results demonstrate that PET/CT adds significant clinical value in selecting appropriate candidates for secondary cytoreduction, mainly by reinforcing potential operability. These findings suggest that PET/CT may provide incremental information during preoperative assessment; however, prospective validation is required.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.